Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Viatris Tipped To Knock Out Crucial Eylea Dosing Patents In US
Lower Preponderance-Of-The-Evidence Standard May Favor Mylan
Aug 17 2022
•
By
Dean Rudge
A decision is due later this year • Source: Shutterstock
(Andriy Popov / Alamy Stock Photo/Alamy Stock Photo)
More from Biosimilars
More from Products
